Skip to content
Menu
Home
About Us
Life Wins
Chairman’s Profile
Board Of Directors
Team Wockhardt
Corporate Milestones
Research & Development
R&D at Wockhardt
New Drug Discovery
Pipeline / Projects
News & Events
Publications
WCK 5222
WCK 4873
WCK 4282
WCK 6777
Biologicals
News & Events
Pipeline / Projects
Publications
R&D Contact
Our Business Verticals
Our Manufacturing Units
Global Footprint
India
UK & Europe
US
Emerging Markets
Products
India Branded Business
Trademark Products
Quality
Digital Footprint
Awards & Recognitions
Investors
From Chairman’s Office
AGM Speech
Letter to Shareowners
Financials
Financials at a Glance
Annual Report
Quarterly Results
Financial Press Releases
Related Party Transactions
Subsidiary Financials
Annual Return
Corporate Governance
Policies & Codes
Committee’s of the Board
Familiarisation programs
Shareholding Pattern
Secretarial Compliance Report
Authorised KMP
Corporate Actions
Announcements / Disclosures
Shareholders Meeting/ Postal ballot
AGM Notice
Proceedings
IEPF
Unclaimed Dividend
Nodal Officer
Analyst/ Investors
Presentation
Audio / Video Recording
Transcript
Shareowner Services
FAQ
Green Initiative
Investor Contact
Stock Quotes
Credit Rating
careers
Introduction
Life@Wockhardt
L&D Initiatives
Voice of Wockhardians
The Wockhardian
Career@Wockhardt
Media
Press Release
Media Coverage
Video Coverage
Media Kit
Sustainability
Contact us
Home
/
2021-2022
/
Page 3
PDF Year:
2021-2022
Home
Chairman’s Letter to Shareowners Q3 FY21 – 22
WOCKHARDT GETS CDSCO NOD FOR EXPORTING UP TO 100 MILLION DOSES OF SPURIK VACCINES
CDSCO Approval for export of Sputnik 08 – 02 – 2022
Financial Results FY22 Q3
Q3 (OCT – DEC 2021) FINANCIAL RESULTS FY22
Appointment of CFO 27 – 01 – 2022
Shareholding Pattern for the Quarter Ended 31st December, 2021
Related Party Transaction Report for Sept. 2021
Chairman’s Letter to Shareowners Q2 FY21 – 22
WBL Acquisition 09 – 11 – 2021
Posts navigation
Previous page
Page
1
Page
2
Page
3
Page
4
…
Page
6
Next page